How many drugs treat Congenital adrenal hyperplasia?

Drug Landscape tracks 7 marketed treatments for Congenital adrenal hyperplasia (deduplicated by molecule). 0 Phase 3 candidates and 0 Phase 2 candidates are in the pipeline.

How do I subscribe to ongoing alerts?

Subscribe to /feed/disease/congenital-adrenal-hyperplasia.xml in Feedly / Inoreader. Every regulatory action, PDUFA date, or trial completion in this treatment area lands in your feed automatically.

Last reviewed 2026-06-10 · How we verify

Congenital adrenal hyperplasia — Treatment Landscape & Competitive Intelligence

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Congenital adrenal hyperplasia (disease) competitive landscape: 7 marketed treatments tracked, 0 Phase 3 candidates, 0 Phase 2 candidates. Recent regulatory actions and upcoming PDUFA dates across the entire treatment set.

7 marketed 0 Phase 3 0 Phase 2 Live · 30-min refresh

Marketed treatment landscape

Approved drugs treating Congenital adrenal hyperplasia, deduplicated by molecule. See the full disease page for line-of-therapy detail.

Drug	Generic	Sponsor	Class	Target	First approval
Depo-Medrol	METHYLPREDNISOLONE ACETATE	Pfizer	Corticosteroid	Glucocorticoid receptor	1959-01-01
Medrol	methylprednisolone	Generic (originally Upjohn/Pfizer)	Glucocorticoid (corticosteroid)	Annexin A1, Short transient receptor potential channel 5, Glucocorticoid receptor	1957-10-01
Prelone	prednisolone	Generic (originally Schering)	Glucocorticoid (corticosteroid)	Annexin A1, Corticosteroid-binding globulin, G-protein coupled bile acid receptor 1	1955-01-01
Cortef	hydrocortisone	Generic (originally Merck/Upjohn)	Corticosteroid [EPC]	Annexin A1, Corticosteroid-binding globulin, Nitric oxide synthase, inducible	1952-01-01
Cortisol	Cortisol	University of Zurich		Annexin A1, Corticosteroid-binding globulin, Nitric oxide synthase, inducible
prednisolon	prednisolon	Hannover Medical School		Annexin A1, Corticosteroid-binding globulin, G-protein coupled bile acid receptor 1
Methylprednisolon	Methylprednisolon	Leiden University Medical Center		Annexin A1, Short transient receptor potential channel 5, Glucocorticoid receptor

Phase 3 pipeline

No Phase 3 pipeline candidates tracked.

Phase 2 pipeline

No Phase 2 pipeline candidates tracked.

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this treatment set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this treatment set.

Sponsor landscape

· 3 drugs in Congenital adrenal hyperplasia
Generic (originally Merck/Upjohn) · 1 drug in Congenital adrenal hyperplasia
Generic (originally Schering) · 1 drug in Congenital adrenal hyperplasia
Generic (originally Upjohn/Pfizer) · 1 drug in Congenital adrenal hyperplasia
Hannover Medical School · 1 drug in Congenital adrenal hyperplasia
Leiden University Medical Center · 1 drug in Congenital adrenal hyperplasia
Pfizer · 1 drug in Congenital adrenal hyperplasia
University of Zurich · 1 drug in Congenital adrenal hyperplasia

Subscribe to ongoing alerts

Every new regulatory action, PDUFA date, or trial completion in Congenital adrenal hyperplasia:

Cite this brief

Drug Landscape (2026). Congenital adrenal hyperplasia — Treatment Landscape & Competitive Intelligence Brief. https://druglandscape.com/ci/disease/congenital-adrenal-hyperplasia. Accessed 2026-06-10.

Congenital adrenal hyperplasia full disease profile — treatment pathway, diagnostics, guidelines
Browse all CI briefs
Build a custom feed

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing